Use Cases & Applications
Structuring disease heterogeneity into interpretable functional states to support patient stratification, biomarker discovery, target prioritization, and drug opportunity mapping.
Core Solutions
Strategic translational capabilities that address core decision points in drug development.
Patient Stratification
Identify biologically coherent patient subgroups using multi-omics digital twins to support cohort enrichment, response analysis, and translational decision-making.
Biomarker Discovery
Discover defensible multi-gene biomarkers through consensus multi-omics modeling and structured biological knowledge annotation, designed for translational and CDx workflows.
Target Discovery & Prioritization
Prioritize therapeutic targets by integrating disease-state biology, pathway directionality, and curated evidence to support early discovery decisions.
Drug Repurposing & Indication Expansion
Map compound-disease alignment across functional disease states to identify indication expansion opportunities and unmet therapeutic niches.
Platform Extensions
Capabilities that deepen programs once a core use case is established.
Target Validation
Assess candidate targets through orthogonal, state-specific evidence to support prioritization before experimental validation.
Custom Digital Twin Atlas Development
Enables disease-specific stratification, biomarker discovery, and target prioritization through reusable reference maps.
Disease Mechanism Discovery
Provides biological context for target prioritization and biomarker interpretation by characterizing state-specific mechanisms.
Companion Diagnostic Development
Translates biomarker discovery outputs into clinically deployable stratification strategies.
Virtual Molecular Profiling from H&E
Supports biomarker discovery and patient stratification by linking histological patterns to molecular states without re-sequencing.
Disease Applications
Examples of how Helomnix structures molecular states in specific hematologic diseases. Each reference implementation demonstrates a reusable analytical workflow for translational research teams.
AML Relapse-Associated Molecular States
Characterizes molecular patterns at diagnosis associated with relapse risk. Provides biological context for consolidation and monitoring research strategies.
DLBCL Pre-Treatment Tumor & Microenvironment Profiling
Profiles tumor and microenvironment features from pre-treatment H&E slides and molecular data. Describes baseline biology before CAR-T therapy to support translational cohort analysis.
MM Differentiation-State Stratification
Classifies myeloma samples according to plasma cell differentiation stage. Enables clear subgroup definition based on maturation biology and supports biomarker exploration.
Experimental & Translational Validation Workflows
In-vitro and perturbation-based workflows that extend Digital Twin analyses into functional validation and preclinical research settings.
Pre-Clinical Drug Validation in In-Vitro Models
Tests whether compounds spare normal plasma cells using a B-to-plasma-cell differentiation model. Examines on-target toxicity at each differentiation stage before animal studies.
Target Validation Using Genetic Perturbation
Uses CRISPR knockout on normal B-cell differentiation models to test whether candidate targets disrupt plasma cell formation. Provides structured evidence on target impact before advancing development programs.
Autoimmunity State Characterization & Compound Profiling
Screens compounds for selective inhibition of pathogenic plasma cell formation while preserving protective B-cell immunity. Supports stage-specific drug assessment across autoimmune indications.
Don't See Your Use Case?
We specialize in custom solutions for hematology drug development. Let's build it together.